Selected 5HT-1D Agonists/MAO Inhibitors Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

When these two medicines are taken together, your body may not process your migraine headache medicine properly.

What might happen:

The blood levels of your migraine headache medicine may increase and cause harmful effects.

What you should do about this interaction:

Contact your healthcare professionals (e.g. doctor or pharmacist) as soon as possible about taking these two medicines together. They may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Maxalt (rizatriptan) US prescribing information. Merck & Co., Inc. December, 2011.
  • 2.Imigran Tablets, Injection, and Nasal Spray (sumatriptan) Australian prescribing information. GlaxoSmithKline February 11, 2002.
  • 3.Imigran Radis (sumaptriptan) UK summary of product characteristics. GlaxoSmithKline UK June 8, 2004.
  • 4.Imitrex Tablets (sumatriptan) US prescribing information. GlaxoSmithKline March, 2012.
  • 5.Imigran Nasal Spray (sumatriptan) UK summary of product characteristics. GlaxoSmithKline UK July 8, 2004.
  • 6.Imitrex Nasal Spray (sumatriptan) US prescribing information. GlaxoSmithKline March, 2012.
  • 7.Imigran Injection (sumatriptan) UK summary of product characteristics. GlaxoSmithKline UK September 19, 2003.
  • 8.Imitrex Injection (sumatriptan) US prescribing information. GlaxoSmithKline October 2, 2012.
  • 9.Imitrex (sumatriptan) CA prescribing information. GlaxoSmithKline Inc. September 22, 2011.
  • 10.Zomig (zolmitriptan) US prescribing information. AstraZeneca Pharmaceuticals LP September, 2012.
  • 11.Zomig (zolmitriptan) UK summary of product characteristics. Zeneca Limited March, 1997.
  • 12.Relpax (eletriptan hydrobromide) US prescribing information. Pfizer Inc. November 27, 2013.
  • 13.Frova (frovatriptan) US prescribing information. Endo Pharmaceuticals October, 2013.
  • 14.Eldepryl (selegiline) US prescribing information. Somerset Pharmaceuticals February, 1997.
  • 15.Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 2007 Nov;152(6):946-51.
  • 16.Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000 Jun;56(3):247-50.
  • 17.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.